Nasus Pharma Ltd. (NSRX)
ASE · Drug Manufacturers - General
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Peers in Drug Manufacturers - General
All in industry →Eli Lilly and Company
Johnson & Johnson
AbbVie Inc.
AstraZeneca PLC
Merck & Co., Inc.
Novartis AG
Amgen Inc.
Gilead Sciences, Inc.
Novo Nordisk A/S
Pfizer Inc.
Recent press releases
Nasus Pharma Ltd. has not issued a press release in this window.
SEC filings
All filings →Nasus Pharma Ltd. has not filed an SEC document in this window.
Insider trades
All insider trades →Nasus Pharma Ltd. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Nasus Pharma Ltd.
All people →Quarterly financials
Full financials →No quarterly financials have been ingested for Nasus Pharma Ltd..